Nano-X Imaging 향후 성장
Future 기준 점검 2/6
Nano-X Imaging은 연간 수입과 매출이 각각 62.5%와 44.1% 증가할 것으로 예상되고 EPS는 연간 66.5%만큼 증가할 것으로 예상됩니다.
핵심 정보
62.5%
이익 성장률
66.47%
EPS 성장률
| Healthcare 이익 성장 | 19.7% |
| 매출 성장률 | 44.1% |
| 향후 자기자본이익률 | n/a |
| 애널리스트 커버리지 | Low |
| 마지막 업데이트 | 30 Jun 2026 |
최근 향후 성장 업데이트
Recent updates
Seeking Alpha • Jun 26
Nano-X Withdraws Guidance, Signals Rocky Road Ahead
Summary Nano-X Imaging Ltd. is downgraded to a sell as its narrative shifts from disruptive growth to execution and survival. NNOX's Q1 revenue rose 53% to $4.3M, but core Nanox.ARC hardware contributed minimally; most revenue stems from teleradiology and AI/Health IT. Withdrawn FY26 guidance, persistent cash burn, and explicit going concern warnings highlight severe liquidity and execution risks. Despite early commercial traction and partnerships, delayed deployments and a shrinking cash runway make near-term dilution highly likely. Read the full article on Seeking Alpha
내러티브 업데이트 • Jun 17
NNOX: New Distribution Agreements Will Support Future Stock Upside Potential
Analysts have reduced their Nano-X Imaging price target by $2 to reflect updated assumptions around long term revenue growth, profit margins, and future P/E multiples. What’s in the News for Nano-X Imaging Nano-X Imaging signed a U.S. distribution agreement through its subsidiary Nanox Impact Inc.내러티브 업데이트 • Jun 03
NNOX: New U.S. Distribution Agreement Will Support Future Imaging Deployment Upside
Analysts have trimmed their Nano-X Imaging price target by $2, reflecting updated views on the stock’s risk profile and long term earnings power after reassessing discount rate assumptions, projected revenue growth and profit margins. What's in the News Auditor Kesselman & Kesselman issued an unqualified opinion in Nano-X Imaging’s latest 20-F filing for the year ended Dec 31, 2025, while expressing doubt about the company’s ability to continue as a going concern.
내러티브 업데이트 • Apr 26
NNOX: Reset Expectations And New Distribution Deals Could Support Upside
Analysts have trimmed their fair value estimate for Nano-X Imaging to $6.65 from $7.75 as they factor in updated assumptions around discount rates, long term revenue growth, profit margins, and future P/E levels. Analyst Commentary Recent research has reset expectations around Nano-X Imaging, with analysts revisiting key inputs such as discount rates, long term revenue assumptions, margin potential, and future P/E levels.내러티브 업데이트 • Apr 12
NNOX: New Distribution Agreements Will Support Future Imaging Deployment Upside
Analysts have kept their $5.00 price target for Nano-X Imaging unchanged, citing only slight adjustments to long term revenue growth assumptions, profit margins and future P/E expectations that do not materially change their view of the stock's valuation. What's in the News Nanox Impact signed a new distribution agreement with Elite Surgical Technologies to deploy the FDA cleared Nanox.ARC tomosynthesis system across Ohio, Indiana, Michigan, Pittsburgh and West Virginia, with expectations for a minimum of five systems in year one and ten in year two, subject to market conditions and customer adoption (Key Developments).내러티브 업데이트 • Mar 28
NNOX: New Global Imaging Deals And AI Platform Access Will Drive Upside
Analysts have adjusted their price target on Nano-X Imaging to $5.00. This keeps it in line with their fair value estimate as they update assumptions around revenue growth, profit margins and future P/E expectations.내러티브 업데이트 • Mar 12
NNOX: New Distribution Deals And AI Partnerships Will Drive Future Upside
Analysts have modestly adjusted their Nano-X Imaging price targets, reflecting small recalibrations to long term revenue growth expectations, slightly higher projected profit margins, and a marginally lower future P/E assumption. What's in the News Nano-X Imaging announced that its US-based subsidiary, Nanox Impact Inc., signed a new distribution agreement with Imperial Imaging Technology LLC to support the commercial rollout of the Nanox.ARC multisource digital tomosynthesis system across several southeastern US states.내러티브 업데이트 • Feb 25
NNOX: New Distribution Agreements And Software Rollout Will Support Future Upside Potential
Analysts have maintained their Nano-X Imaging fair value estimate at $5.00, citing only minor adjustments in projected revenue growth, profit margin, and future P/E assumptions instead of a significant change in their overall view. What's in the News Nano-X Imaging signed a distribution agreement with Intec SRL, which will act as the exclusive distributor for the Nanox.ARC system and related services in Argentina, covering marketing, distribution, installation, support, demonstrations, clinical evaluations, and training activities, with commercialization subject to required local regulatory approvals (Key Developments).내러티브 업데이트 • Feb 10
NNOX: New Collaborations And Equity Raise Will Support Future Upside Potential
Analysts have reduced their fair value estimate for Nano-X Imaging from US$7.00 to US$5.00, citing updated assumptions around discount rates, long term revenue growth, profit margins, and a lower future P/E multiple. What's in the News The FDA granted 510(k) clearance for TAP2D, a cloud enabled image enhancement capability for the Nanox.ARC and Nanox.ARC X systems.내러티브 업데이트 • Jan 27
NNOX: New Partnerships And Equity Raise Will Support Future Upside Potential
Analysts have modestly lifted their price target on Nano-X Imaging, citing an unchanged fair value at US$7.00, along with very large forecast revenue growth and slightly adjusted assumptions for the discount rate, profit margin and future P/E. What's in the News Nano-X Imaging filed and then completed a follow on equity offering of 3,826,530 ordinary shares, raising about US$15.0 million in a registered direct offering at US$3.92 per share, with a US$0.20 discount per share (Key Developments).내러티브 업데이트 • Jan 12
NNOX: New Partnerships And EU Approval Will Support Future Upside Potential
Analysts have lifted their price target on Nano-X Imaging to US$7.00. The updated view reflects higher modeled revenue growth and a lower projected future P/E multiple, while fair value and discount rate assumptions remain essentially unchanged.내러티브 업데이트 • Dec 26
NNOX: Expanding AI Imaging Partnerships Will Drive Future Global Deployment Upside
Analysts have nudged their price target on Nano-X Imaging slightly higher to reflect modest improvements in projected revenue growth, profit margins, and a marginally lower future price to earnings multiple. However, they have left their fair value estimate effectively unchanged at approximately 7.00 dollars per share.내러티브 업데이트 • Dec 12
NNOX Will Benefit From Expanding AI Imaging Partnerships And Growing Global Deployments
Analysts have raised their price target on Nano-X Imaging by approximately 17 percent to reflect stronger projected revenue growth and modestly improved long term profitability, which is partially offset by a slightly higher discount rate and a lower assumed future price to earnings multiple. What's in the News Nano-X Imaging completed a registered direct follow on equity offering of approximately $15 million, issuing 3,826,530 ordinary shares at $3.92 per share to support growth initiatives (company filing).분석 기사 • Oct 31
Nano-X Imaging (NASDAQ:NNOX) Has Debt But No Earnings; Should You Worry?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...내러티브 업데이트 • Aug 15
Digital Diagnostics And AI Will Open Global Markets
With both Net Profit Margin and Consensus Revenue Growth forecasts holding steady, analyst expectations for Nano-X Imaging remain unchanged, maintaining the price target at $7.75. What's in the News Nano-X Imaging announced a clinical and educational collaboration with Keiser University to deploy the Nanox.ARC imaging system at the Sarasota campus for training and demonstrations.분석 기사 • May 27
Analysts Have Just Cut Their Nano-X Imaging Ltd. (NASDAQ:NNOX) Revenue Estimates By 39%
One thing we could say about the analysts on Nano-X Imaging Ltd. ( NASDAQ:NNOX ) - they aren't optimistic, having just...
새로운 내러티브 • Apr 27
FDA And CE Mark Approvals Will Open European Imaging Markets
FDA clearance and European market entry through CE mark approval may significantly enhance Nano-X Imaging's revenue and market presence.분석 기사 • Apr 01
Is Nano-X Imaging (NASDAQ:NNOX) Weighed On By Its Debt Load?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Seeking Alpha • Feb 14
Nano-X Imaging: When Will The Hockey Stick Growth Happen?
Summary Nano-X Imaging is my speculative play for disruptive innovation in the biotech sector. With the S&P 500 at historical highs, lagging sectors like healthcare seem relatively attractive. The biotech sector's large market size and potential make it an intriguing investment opportunity. The AI push in health sector is a long-term tailwind. NNOX is positioned well in offering real value from the AI system. Expect Nano-X to reach inflection point for revenue growth due to FDA approvals and the huge need for cost-effective X-ray monitoring and analyzing solutions. Read the full article on Seeking AlphaSeeking Alpha • Jan 04
Nano-X Imaging's Recent Surge Is Undeserved
Summary Nano-X Imaging shares surged 50.8% in a month, but I maintain a "sell' rating due to overvaluation and poor fundamentals. Despite some positive developments, Nano-X generates minimal revenue, significant net losses, and cash outflows, necessitating future capital raises. Recent FDA clearances and accolades are promising, but there's no concrete evidence that their technologies will achieve commercial success. The company's declining net cash balance and unjustified valuation reinforce my bearish stance on Nano-X Imaging. Read the full article on Seeking Alpha분석 기사 • Dec 05
We Think Some Shareholders May Hesitate To Increase Nano-X Imaging Ltd.'s (NASDAQ:NNOX) CEO Compensation
Key Insights Nano-X Imaging to hold its Annual General Meeting on 10th of December Total pay for CEO Erez Meltzer...분석 기사 • Nov 25
Is Nano-X Imaging (NASDAQ:NNOX) Weighed On By Its Debt Load?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...Seeking Alpha • Sep 29
Nano-X Imaging: Bold Vision, Bearish Momentum, And High Investor Risk
Summary Nano-X Imaging has seen a significant decline in stock value, shedding over 37% since February, with no strong catalysts to reverse the trend. Nvidia’s small stake in Nano-X briefly boosted the stock, but without further investment or partnership, investor excitement has waned. Persistent financial losses, slow revenue growth, and limited global reach make Nano-X a high-risk investment with potential for further value erosion. Read the full article on Seeking Alpha분석 기사 • Apr 05
Is Nano-X Imaging (NASDAQ:NNOX) Weighed On By Its Debt Load?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Seeking Alpha • Apr 01
Nano-X Imaging: System Deployments Finally Begin
Summary Nano-X Imaging is executing its long-awaited roll-out strategy with multiple Nanox.ARC system deployments in the U.S. The company has also made progress in Africa and Latin America with installations and distribution agreements. However, financial performance is still lagging with scant details on how Nano-X will scale up to commercial scale. The story is improving, but there are still too many concerns for me to invest in NNOX stock. Read the full article on Seeking Alpha이익 및 매출 성장 예측
| 날짜 | 매출 | 이익 | 자유현금흐름 | 영업현금흐름 | 평균 애널리스트 수 |
|---|---|---|---|---|---|
| 12/31/2028 | 100 | -15 | N/A | N/A | 2 |
| 12/31/2027 | 51 | -29 | N/A | N/A | 3 |
| 12/31/2026 | 27 | -43 | N/A | -31 | 3 |
| 3/31/2026 | 15 | -76 | -50 | -44 | N/A |
| 12/31/2025 | 13 | -75 | -45 | -41 | N/A |
| 9/30/2025 | 12 | -56 | -45 | -41 | N/A |
| 6/30/2025 | 12 | -56 | -42 | -38 | N/A |
| 3/31/2025 | 12 | -55 | -41 | -37 | N/A |
| 12/31/2024 | 11 | -54 | -39 | -37 | N/A |
| 9/30/2024 | 11 | -50 | -41 | -39 | N/A |
| 6/30/2024 | 10 | -57 | -44 | -42 | N/A |
| 3/31/2024 | 10 | -61 | -45 | -44 | N/A |
| 12/31/2023 | 10 | -61 | -48 | -45 | N/A |
| 9/30/2023 | 10 | -103 | -49 | -47 | N/A |
| 6/30/2023 | 10 | -101 | -45 | -42 | N/A |
| 3/31/2023 | 9 | -103 | -48 | -43 | N/A |
| 12/31/2022 | 9 | -113 | -51 | -43 | N/A |
| 9/30/2022 | 8 | -82 | -63 | -50 | N/A |
| 6/30/2022 | 5 | -77 | -65 | -49 | N/A |
| 3/31/2022 | 3 | -71 | -66 | -45 | N/A |
| 12/31/2021 | 1 | -62 | -61 | -38 | N/A |
| 9/30/2021 | N/A | -59 | N/A | N/A | N/A |
| 6/30/2021 | N/A | -56 | N/A | N/A | N/A |
| 3/31/2021 | N/A | -49 | N/A | N/A | N/A |
| 12/31/2020 | N/A | -44 | -36 | -22 | N/A |
| 9/30/2020 | N/A | -44 | -13 | -12 | N/A |
| 6/30/2020 | N/A | -35 | -9 | -9 | N/A |
| 3/31/2020 | N/A | -29 | N/A | N/A | N/A |
| 12/31/2019 | N/A | -23 | N/A | -6 | N/A |
애널리스트 향후 성장 전망
수입 대 저축률: NNOX 향후 3년 동안 수익성이 없을 것으로 예상됩니다.
수익 vs 시장: NNOX 향후 3년 동안 수익성이 없을 것으로 예상됩니다.
고성장 수익: NNOX 향후 3년 동안 수익성이 없을 것으로 예상됩니다.
수익 대 시장: NNOX 의 수익(연간 44.1%)이 US 시장(연간 12.8%)보다 빠르게 성장할 것으로 예상됩니다.
고성장 매출: NNOX 의 수익(연간 44.1%)은 연간 20%보다 빠르게 증가할 것으로 예상됩니다.
주당순이익 성장 예측
향후 자기자본이익률
미래 ROE: NNOX의 자본 수익률이 3년 후 높을 것으로 예상되는지 판단하기에 데이터가 부족합니다.
성장 기업 찾아보기
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/06/30 20:55 |
| 종가 | 2026/06/30 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Nano-X Imaging Ltd.는 9명의 분석가가 다루고 있습니다. 이 중 3명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Benjamin Haynor | Alliance Global Partners |
| Scott Henry | Alliance Global Partners |
| Ravi Misra | Berenberg |